Fletcher W S, Lum S S, Nance R W, Pommier R F, O'Dorisio M S
Section of Surgical Oncology, Oregon Health Sciences University, Portland, USA.
Yale J Biol Med. 1997 Sep-Dec;70(5-6):561-3.
On the basis that melanomas are of neural crest origin and might contain somatostatin receptors, the authors utilized 111In Pentetreotide (OctreoScan) to image 16 melanoma patients with known sites of disease. Twelve of 16 patients were positive with 38 percent imaging all sites. No lesion less than 1.5 cm imaged nor did one ocular and one amelanotic melanoma. Of the five described somatostatin receptors, OctreoScan binds only 2 and 5 suggesting that not all melanomas contain those receptors. It is concluded that melanomas contain somatostatin receptors and that this property might be used for imaging, tumor suppression with Octreotide, and/or as a target for Octreotide labelled with therapeutic agents such as immune complexes, chemotherapeutic agents or high energy radioisotopes.
基于黑色素瘤起源于神经嵴且可能含有生长抑素受体,作者使用铟-111喷替肽(奥曲肽扫描)对16例已知疾病部位的黑色素瘤患者进行成像。16例患者中有12例呈阳性,38%的患者所有部位均成像。小于1.5厘米的病灶未成像,眼部黑色素瘤和无色素性黑色素瘤也未成像。在所述的5种生长抑素受体中,奥曲肽扫描仅与受体2和5结合,这表明并非所有黑色素瘤都含有这些受体。结论是黑色素瘤含有生长抑素受体,这一特性可用于成像、用奥曲肽抑制肿瘤和/或作为用免疫复合物、化疗药物或高能放射性同位素等治疗剂标记的奥曲肽的靶点。